Statistics

Number of Journals8
Number of Issues54
Number of Articles392
Article View138,427
PDF Download97,282
Daya, A., Lookzadeh, M., Noorishadkam, M., Mirjalili, S., Ekraminasab, S. (2023). The Effect of the Iranian Surfactant (Beraksurf) in the Treatment of Respiratory Distress Syndrome in Premature Neonates. Shahid Sadoughi University of Medical Sciences- Journal Management System, 6(1), 10-16. doi: 10.18502/wjpn.v6i1.14248
Ahmad Daya; Mohamad Hosein Lookzadeh; Mahmood Noorishadkam; Seyed Reza Mirjalili; Sedigheh Ekraminasab. "The Effect of the Iranian Surfactant (Beraksurf) in the Treatment of Respiratory Distress Syndrome in Premature Neonates". Shahid Sadoughi University of Medical Sciences- Journal Management System, 6, 1, 2023, 10-16. doi: 10.18502/wjpn.v6i1.14248
Daya, A., Lookzadeh, M., Noorishadkam, M., Mirjalili, S., Ekraminasab, S. (2023). 'The Effect of the Iranian Surfactant (Beraksurf) in the Treatment of Respiratory Distress Syndrome in Premature Neonates', Shahid Sadoughi University of Medical Sciences- Journal Management System, 6(1), pp. 10-16. doi: 10.18502/wjpn.v6i1.14248
Daya, A., Lookzadeh, M., Noorishadkam, M., Mirjalili, S., Ekraminasab, S. The Effect of the Iranian Surfactant (Beraksurf) in the Treatment of Respiratory Distress Syndrome in Premature Neonates. Shahid Sadoughi University of Medical Sciences- Journal Management System, 2023; 6(1): 10-16. doi: 10.18502/wjpn.v6i1.14248

The Effect of the Iranian Surfactant (Beraksurf) in the Treatment of Respiratory Distress Syndrome in Premature Neonates

World Journal of Peri & Neonatology
Article 2, Volume 6, Issue 1, December 2023, Pages 10-16    PDF (392.29 K)
Document Type: Original Article
DOI: 10.18502/wjpn.v6i1.14248
Authors
Ahmad Daya1; Mohamad Hosein Lookzadeh* 1; Mahmood Noorishadkam1; Seyed Reza Mirjalili1; Sedigheh Ekraminasab1, 2
1Mother and Newborn Health Research Center, Shahid Sadoughi Hospital, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Background: Respiratory distress syndrome (RDS) is a type of lung development defect that is commonly seen in preterm births. Deficiency of pulmonary surfactant due to immaturity is the principal cause of RDS in premature infants. This study was conducted with the aim of Iranian surfactant (Beraksurf)’s effect in treating RDS in premature neonates.
Methods: In this study, all infants who were premature and had RDS were included in the study. Also, the infants were examined based on primary and secondary outcomes. Primary outcomes include the duration of need for nasal continuous positive airway pressure (NCPAP), number of surfactant administration, and secondary outcomes including bronchopulmonary dysplasia (BPD), pneumothorax, and pulmonary hemorrhage.
Results: A total of 162 neonates with a mean gestational age of 31.28 ± 2.58 weeks were evaluated. The 120 people (74.1%) used medicine only on the first day, 19 people on other days, and 23 people on the first and second day. Also, 141 children (87.6%) were discharged from the hospital and unfortunately, 20 children (12.4%) died. The prevalence of pneumothorax, BPD, and pulmonary hemorrhage was 1.8%, 1.2%, and 1.2% respectively. Also, 69.7% needed less than five days of mechanical ventilation and 30.2% needed more than 5 days of mechanical ventilation.
Conclusion: Considering getting better treatment results from taking Beraksurf, as well as fewer side effects and the fact that this drug is Iranian, and due to its easier access and cheaper price, we can pay more attention to the prescription of this drug.
Keywords
Premature Birth; Respiratory Distress Syndrome; Pulmonary Surfactants; Newborn; Pneumothorax; Bronchopulmonary Dysplasia
References
1. Marinonio ASS, Costa-Nobre DT, Miyoshi MH, de Cassia Xavier Balda R, Areco KCN, Konstantyner T, et al. Clusters of preterm live births and respiratory distress syndrome-associated neonatal deaths: spatial distribution and cooccurrence patterns. BMC Public Health 2022; 22(1): 1226.
2. Dilli D, Çakmakçı E, Akduman H, Oktem A, Aydoğan S, Çitli R, et al. Comparison of three natural surfactants according to lung ultrasonography scores in newborns with respiratory distress syndrome. J Matern Neonatal Med 2021; 34(10): 1634-40.
3. Magnani JE, Donn SM. Persistent respiratory distress in the term neonate: Genetic surfactant deficiency diseases. Curr Pediatr Rev 2019; 16(1): 17-25.
4. Luna MS, Bacher P, Unnebrink K, Martinez-Tristani M, Navarro CR. Beractant and poractant alfa in premature neonates with respiratory distress syndrome : a systematic review of real-world evidence studies and randomized controlled trials. J Perinatol 2020; 40(8): 1121-34.
5. Najafian B, Karimi-Sari H, Khosravi MH, Nikjoo N, Amin S, Shohrati M. Comparison of efficacy and safety of two available natural surfactants in Iran, Curosurf and Survanta in treatment of neonatal respiratory distress syndrome: A randomized clinical trial. Contemp Clin Trials Commun 2016; 3: 55-9.
6. Baer B, Souza LMP, Pimentel AS, Veldhuizen RAW. New insights into exogenous surfactant as a carrier of pulmonary therapeutics. Biochem Pharmacol 2019; 164: 64-73.
7. Beraksurf. [Online]. [cited 2019]; Avilable from: URL: http://beraksurf.com/AboutBeraksurf.html
8. Bulimba M, Cosmas J, Abdallah Y, Massawe A, Manji K. Early outcomes of preterm neonates with respiratory distress syndrome admitted at Muhimbili National Hospital, a prospective study. BMC Pediatr 2022; 22(1): 731.
9. Qiu C, Ma C, Fan N, Zhang X, Zheng G. Comparative efficacy of pulmonary surfactant in respiratory distress syndrome in preterm infants: a Bayesian network meta-analysis. Arch Med Sci 2020; 19(5): 1446-53.
10. Reuter S, Moser C, Baack M. Respiratory distress in the newborn infant. Pediatr Rev 2014; 35(10): 417-29.
11. Lookzadeh MH, Bahrami R, Ekraminasab S. Prevalence of urinary tract infection in Iranian newborns with jaundice: A meta-analysis. World J Peri &b Neonatol 2021; 4(1): 40-9.
12. Ekraminasab S, Manzourolhojeh M. Prevalence of sepsis among iranian newborns with jaundice: A meta-analysis based on cross-sectional studies. World J Peri & Neonatol 2022; 4(2): 115-23.
13. Yadav S, Lee B, Kamity R. Neonatal respiratory distress syndrome. StatPearls 2021. p. 1-18.
14. Sankar MJ, Gupta N, Jain K, Agarwal R, Paul VK. Efficacy and safety of surfactant replacement therapy for preterm neonates with respiratory distress syndrome in low- and middle-income countries: A systematic review. J Perinatol 2016; 36(S1): S35-47.
15. Khawar H, Marwaha K. Surfactant. StatPearls 2023.
16. Sweet DG, Carnielli VP, Greisen G, Hallman M, Klebermass-Schrehof K, Ozek E, et al. European consensus guidelines on the management of respiratory distress syndrome: 2022 update. Neonatology 2023; 120(1): 3-23.
17. Baghal Safa F, Noorishadkam M, Lookzade MH, Mirjalili SR, Ekraminasab S. Budesonide and surfactant combination for treatment of respiratory distress syndrome in preterm neonates and evaluation outcomes. J Clin Neonatol 2023; 12(4): In press.
18. Nourollahi S, Hashemi F, Shafiei E, Pirinejad O. Comparing the effectiveness of curosurf and beraksurf in the treatment of respiratory distress in premature infants. Int J Pediatr 2022; 10(5): 15992-7.
19. Golshan-Tafti M, Ekraminasab S, Bahrami R, Asadian F. Mortality rate in hospitalized pediatric patients with COVID-19 infection in Iran: A systematic review and meta-analysis. World J Peri & Neonatol 2022; 5(1): 30-9.
20. Lookzadeh MH, Ekraminasab S, Baghalsafa F. Outcome of a neonate norn to a mother with COVID-19: A case report of vertical transmission. World J Peri & Neonatol 2022; 4(2): 124-9.
21. Bahrami R, Ekraminasab S, Asadian F. A survey on cardiac complications of COVID-19 in infants. World J Peri & Neonatol 2021; 4(1): 50-9.
22. Baghalsafa F, Neamatzadeh H, Ekraminasab S. Death of a 3 month-old infected infant with dilated cardiomyopathy after COVID-19 infection: A case report. World J Peri & Neonatol 2021; 4(1): 60-4.
23. Saeedi R, Hamedi A, Javadi A, Gholami Robatsangi M, Kaka Dinparvar S. Comparison of side effect of survanta and curosurf in decreasing mortality due to respiratory distress syndrome (RDS) in premature infants admitted in NICU of Ghaem Hospital on 2006-2008. Iran J Neonatol 2013; 4(3): 7-12.
24. Mirzarahimi M, Barak M. Comparison efficacy of Curosurf and Survanta in preterm infants with respiratory distress syndrome. Pak J Pharm Sci 2018; 31(2): 469-72.
25. Gharehbaghi MM, Sakha SHP, Ghojazadeh M, Firoozi F. Complications among premature neonates treated with beractant and poractant alfa. Indian J Pediatr 2010; 77(7): 751-4.

Statistics
Article View: 263
PDF Download: 262


Journal Management System. Powered by Sinaweb